The most effective approved weight-loss drug as of 2026, with the largest trial programme in this library after semaglutide, an outcomes record that is strong on weight and still filling in on hearts, and an access story that changed more in the last eighteen months than in the three years before.

Summary

Tirzepatide is a once-weekly injectable agonist of two gut hormone receptors, GIP and GLP-1. It is sold as Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnoea; the molecule and the pens are the same.1
In SURMOUNT-1, 72 weeks at 15 mg reduced body weight by 20.9 percent against 3.1 percent on placebo, and 57 percent of participants lost at least a fifth of their weight.2
In a direct comparison, tirzepatide produced more weight loss than semaglutide: 20.2 percent against 13.7 percent at 72 weeks.3
Stopping reverses it. Participants switched to placebo after 36 weeks regained 14 percent of body weight in the following year; those who continued lost a further 5.5 percent.4
Three years of treatment in people with obesity and prediabetes cut progression to type 2 diabetes from 13.3 percent to 1.3 percent.5
The cardiovascular outcomes trial, in 13,299 people with diabetes and heart disease, found tirzepatide non-inferior to dulaglutide but did not demonstrate superiority.6 In heart failure with preserved ejection fraction, it reduced the combined risk of cardiovascular death or worsening heart failure by 38 percent.7
Gastrointestinal side effects are the rule during dose escalation. Discontinuation for adverse events was 4 to 7 percent on drug against 2.6 percent on placebo in SURMOUNT-1.2
The label carries a boxed warning for thyroid C-cell tumours seen in rats. In February 2026 the FDA removed the warning about suicidal behaviour and ideation from the label.1
The compounding era ended when the FDA declared the shortage resolved on 19 December 2024; enforcement discretion for compounders expired in February and March 2025.8

The Most Common Error About This Compound

Assuming that the larger weight loss means the larger outcomes benefit. Tirzepatide beats semaglutide on the scale by a wide and reproduced margin.3 Semaglutide has a completed cardiovascular outcomes trial in obesity without diabetes showing a 20 percent reduction in major events; tirzepatide's equivalent trial in that population has not reported, and its diabetes outcomes trial showed non-inferiority to an active comparator rather than a reduction against placebo.6 More weight loss is a reasonable basis for expecting more benefit. It is not yet a demonstration of it.

Basics and Mechanism

What Is Tirzepatide?

A 39-amino-acid synthetic peptide based on the sequence of GIP, glucose-dependent insulinotropic polypeptide, engineered to activate both the GIP receptor and the GLP-1 receptor, with a fatty acid chain attached so that it binds albumin and lasts a week. Lilly's shorthand is "twincretin." Both hormones are released by the gut after eating and signal to the pancreas and brain; GLP-1 receptor agonists like semaglutide use one of those pathways, tirzepatide uses both.2

Why adding GIP helps is still being worked out. GIP alone is a weak weight-loss agent, and GIP receptor antagonists also cause weight loss in animals, which is a paradox the field has not resolved. What is not in doubt is the empirical result: the dual agonist produces more weight loss and more glucose lowering than the single agonist at the doses tested.9 3

Is Mounjaro the Same as Zepbound?

Yes. They are the same molecule at the same doses in the same pens, with different labels and different prices. Mounjaro was approved on 13 May 2022 for type 2 diabetes; Zepbound on 8 November 2023 for chronic weight management, with moderate-to-severe obstructive sleep apnoea in adults with obesity added on 20 December 2024. The Zepbound label states that coadministration with other tirzepatide products or with any GLP-1 receptor agonist is not recommended.1 Which name is on the box determines which indication is being billed for and, therefore, whether insurance pays. It does not determine what the drug does.

Is It Insulin?

No. Tirzepatide stimulates the body's own insulin release in response to glucose and suppresses glucagon, which is why hypoglycaemia is rare unless it is combined with insulin or a sulfonylurea. The label warns of that combination specifically.1

Dosing as Studied

What Schedule Was Used?

Every trial started at 2.5 mg weekly for four weeks and increased in 2.5 mg steps at intervals of at least four weeks, to a maintenance dose of 5, 10 or 15 mg. In SURMOUNT-1 the escalation to 15 mg took 20 weeks.2 The label reproduces that: 2.5 mg is a starting dose and "is not approved as a maintenance dosage"; maintenance is 5, 10 or 15 mg for weight, and 10 or 15 mg for sleep apnoea.1

Does the Dose Matter?

Yes, and less than the range suggests. In SURMOUNT-1, weight loss at 72 weeks was 15.0 percent at 5 mg, 19.5 percent at 10 mg and 20.9 percent at 15 mg.2 Most of the effect is present at the lowest maintenance dose; the top dose adds about six percentage points over it and less than two over the middle dose. That shape has consequences for both tolerability and cost, and the label's instruction to "consider treatment response and tolerability when selecting the maintenance dosage" is written around it.1

A 2026 real-world study of 260 patients in Greek endocrinology clinics, most on low-to-moderate doses, found 94 percent lost at least 5 percent and 47 percent at least 15 percent by six months, with 80 percent still on treatment.10 Outside a trial, people are not racing to 15 mg, and they are still losing weight.

What to Expect Over Time

How Much Weight, and How Fast?

SURMOUNT-1 randomised 2,539 adults with obesity, or overweight with a complication, without diabetes. Mean starting weight was 104.8 kg. At 72 weeks, 85 to 91 percent on tirzepatide had lost at least 5 percent, against 35 percent on placebo; half of those on 10 mg and 57 percent on 15 mg had lost at least 20 percent, against 3 percent on placebo.2

Weight loss is front-loaded but continues for over a year. By the 176-week extension, participants with prediabetes were at −19.7 percent on 15 mg and −18.7 on 10 mg, against −1.3 percent on placebo, and no new safety signal had emerged.5 The plateau, when it comes, is a property of the dose and the person, not a sign the drug has stopped working; the SURMOUNT-4 continuation arm kept losing after 36 weeks.4

In People With Type 2 Diabetes

Less. SURMOUNT-2, in 938 adults with obesity and type 2 diabetes, found 12.8 percent at 10 mg and 14.7 percent at 15 mg against 3.2 percent on placebo at 72 weeks.11 The same gap exists for semaglutide and for every drug in the class; people with diabetes lose less weight on incretin therapy, for reasons that are only partly understood.

What Does It Do to Blood Sugar?

In SURPASS-2, in 1,879 people with type 2 diabetes, tirzepatide at 5, 10 and 15 mg reduced HbA1c by 2.01, 2.24 and 2.30 percentage points over 40 weeks against 1.86 for semaglutide 1 mg, and was superior at every dose; weight loss was 1.9 to 5.5 kg greater.9 Severe hypoglycaemia was rare, under 2 percent at any dose, without insulin.

Does It Prevent Diabetes?

In people who already have prediabetes, yes, and the effect size is large. In the SURMOUNT-1 extension, 1.3 percent on tirzepatide progressed to type 2 diabetes over 176 weeks against 13.3 percent on placebo, a hazard ratio of 0.07. After 17 weeks off drug the figures were 2.4 and 13.7 percent.5 The off-treatment rebound in that short window was small; whether it stays small over years is unknown.

Stopping, Maintenance and Rebound

What Happens If Treatment Stops?

SURMOUNT-4 is the clearest withdrawal trial in the class. After 36 weeks of open-label tirzepatide, during which participants lost 20.9 percent, 670 were randomised to continue or switch to placebo for a year. The continuation group changed −5.5 percent; the placebo group gained 14.0 percent. At week 88, 89.5 percent of those continuing had kept at least 80 percent of their loss, against 16.6 percent of those withdrawn. Overall change from the start was −25.3 percent on drug and −9.9 percent after withdrawal.4

So a year off the drug returned roughly two thirds of what had been lost, which is the same proportion the semaglutide withdrawal extension found. Tirzepatide is a maintenance drug. The label's indication is to "reduce excess body weight and maintain weight reduction long term," and the second half of that phrase is the one the trial data describe.1

Is There a Published Taper Protocol?

No. SURMOUNT-4 tested abrupt withdrawal to placebo. No trial has tested stepping down the dose, spacing out injections, or any other strategy for keeping weight off with less drug. Those strategies are widely used in practice, and every one of them is untested.

What About After Lifestyle Treatment?

SURMOUNT-3 answered a different question: what tirzepatide adds after a person has already lost weight the hard way. Participants who lost at least 5 percent through 12 weeks of intensive lifestyle intervention were randomised to tirzepatide or placebo for 72 weeks. Those on drug lost a further 18.4 percent; those on placebo regained 2.5 percent.12

Comparisons

Tirzepatide Against Semaglutide

SURMOUNT-5 was the head-to-head, in 751 adults with obesity without diabetes, each drug at its maximum tolerated dose, for 72 weeks, open-label. Weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide; waist circumference fell 18.4 cm against 13.0. More people on tirzepatide reached every threshold from 10 to 25 percent. Gastrointestinal adverse events were the most common in both arms.3 The trial was funded by Lilly and was not blinded, which matters less for a weight endpoint than for a subjective one.

In diabetes, SURPASS-2 found the same direction at every dose, against semaglutide 1 mg rather than 2.4 mg.9 A 2025 systematic review of 26 placebo-controlled trials in people without diabetes put the placebo-adjusted figures at up to 17.8 percent for tirzepatide 15 mg, 13.9 for semaglutide 2.4 mg and 5.8 for liraglutide, while noting the absence of head-to-head data for most comparisons.13

Against What Is Coming

The same review put retatrutide, Lilly's triple agonist, at up to 22.1 percent in Phase 2.13 Retatrutide is not approved and is covered on its own library entry. Tirzepatide is the most effective drug a person can actually be prescribed.

Outcomes Beyond Weight

Cardiovascular

This is where the record is most often overstated. SURPASS-CVOT randomised 13,299 people with type 2 diabetes and established cardiovascular disease to tirzepatide or dulaglutide, a GLP-1 agonist already shown to reduce events. The primary endpoint of cardiovascular death, heart attack or stroke occurred in 12.2 percent on tirzepatide and 13.1 percent on dulaglutide, hazard ratio 0.92, with a confidence interval of 0.83 to 1.01. That met non-inferiority and did not meet superiority.6

Read carefully, that is a good result: tirzepatide is at least as protective as a drug with proven benefit, in a high-risk population, and the point estimate favours it. It is not a placebo-controlled demonstration of cardiovascular benefit, and there is none for tirzepatide in obesity without diabetes; that trial, SURMOUNT-MMO, is ongoing. Semaglutide has that result. Tirzepatide does not yet.

Heart Failure

SUMMIT randomised 731 people with heart failure with preserved ejection fraction and obesity to tirzepatide or placebo for a median of 104 weeks. Cardiovascular death or worsening heart failure occurred in 9.9 percent on drug and 15.3 percent on placebo, hazard ratio 0.62; worsening heart failure events alone fell by 46 percent. Quality-of-life scores improved by 6.9 points more than placebo. Cardiovascular deaths were few and numerically higher on drug, 8 against 5, a difference the trial was not powered to interpret.7 This is the strongest outcomes result tirzepatide has, and it is not yet a labelled indication.

Sleep Apnoea

Two 52-week trials in adults with moderate-to-severe obstructive sleep apnoea and obesity, one in people not using positive airway pressure and one in people who were. The apnoea-hypopnoea index fell by 25.3 and 29.3 events per hour on tirzepatide against 5.3 and 5.5 on placebo, with improvements in hypoxic burden, inflammation, blood pressure and patient-reported sleep.14 This became a labelled indication in December 2024, which matters for insurance more than for pharmacology.

Liver

SYNERGY-NASH, a Phase 2 trial in 190 people with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and moderate or severe fibrosis, found MASH resolution without worsening fibrosis in 44, 56 and 62 percent at 5, 10 and 15 mg against 10 percent on placebo, and fibrosis improvement in 51 to 55 percent against 30.15 A Phase 3 programme is under way; the indication does not exist yet.

Kidney

A post hoc analysis of SURPASS-CVOT reported cardiorenal outcomes favouring tirzepatide over dulaglutide.16 A dedicated kidney outcomes trial has not reported. Post hoc analyses generate hypotheses; they do not establish indications.

Gastrointestinal Side Effects

How Common Are They?

The most common adverse reactions on the Zepbound label, at 5 percent or more, are nausea, diarrhoea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss and reflux.1 In SURMOUNT-1 the events were mostly mild to moderate and clustered during dose escalation.2 The 2025 systematic review across the class put gastrointestinal adverse events at 47 to 84 percent on drug against 13 to 63 percent on placebo.13

How Often Do They Cause People to Stop?

In SURMOUNT-1, 4.3, 7.1 and 6.2 percent at 5, 10 and 15 mg, against 2.6 percent on placebo.2 In the Greek real-world cohort, discontinuation was 20 percent by six months, but mostly for reaching a goal, cost or non-response rather than side effects.10 The label now carries a strengthened warning, revised February 2026, that gastrointestinal reactions can be severe, and states the drug is not recommended in severe gastroparesis.1

Serious Risks

Thyroid

The boxed warning. In rats, tirzepatide causes dose- and duration-dependent thyroid C-cell tumours at clinically relevant exposures; whether it does so in humans "has not been determined." The drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2, and the label says routine calcitonin or ultrasound monitoring is of uncertain value.1 This is the same warning every long-acting GLP-1 agonist carries, based on the same rodent biology, and after nearly twenty years of the class in humans no clear signal has emerged. It remains boxed because the question cannot be closed.

Pancreas, Gallbladder, Kidneys

Acute pancreatitis has been observed and the label says to discontinue if suspected. Gallbladder disease occurred in trials: cholelithiasis in 1.1 percent of Zepbound-treated patients in the pooled pivotal studies. Acute kidney injury, mostly from dehydration during vomiting or diarrhoea, was reported in 0.5 percent against 0.2 on placebo.1 None of these is common; all of them are the reason the drug is prescribed rather than sold.

Anaesthesia

The label warns of pulmonary aspiration during general anaesthesia or deep sedation, because the drug slows stomach emptying. Anyone scheduled for a procedure should tell the anaesthetist they are on it.1

Hypersensitivity

Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported after marketing, and known serious hypersensitivity is now a contraindication.1

Eyes

Diabetic retinopathy complications in people with type 2 diabetes remain a labelled warning, revised in August 2026, and the guidance is to monitor patients with a history of retinopathy.1 The rapid improvement in blood sugar, rather than the drug itself, is the suspected mechanism.

Mental Health

Does Tirzepatide Increase Suicide Risk?

The evidence says no, and in February 2026 the label caught up with it. The Zepbound label had carried a warning to monitor for depression and suicidal ideation, inherited from the class. Its revision history now records "Suicidal Behavior and Ideation (Removed) 02/2026."1 That followed the FDA's own review of the class, which found no evidence of a causal link, and multiple large observational analyses pointing the same way. The ONPEPS semaglutide entry covers the underlying question in detail; the answer transfers.

Body Composition and Muscle

How Much Muscle Is Lost?

In a DXA substudy of 160 SURMOUNT-1 participants, 72 weeks of tirzepatide reduced body weight by 21.3 percent, fat mass by 33.9 percent and lean mass by 10.9 percent. Of the weight lost, about 75 percent was fat and 25 percent lean, and the proportion was the same on placebo and across subgroups by sex, age and amount lost.17

Two things follow. The lean fraction is what ordinary weight loss produces, not a peculiarity of the drug. And "lean mass" on DXA includes water, organ tissue and the muscle that was carrying the lost fat; it is not a direct measure of strength or function. Whether a quarter of the loss being lean matters for an individual depends on how much muscle they started with and what they do while losing, which is why every trial included a lifestyle programme and the label says "in combination with a reduced-calorie diet and increased physical activity."1

Other Side Effects

Does Tirzepatide Cause Hair Loss?

Hair loss is on the label at 5 percent or more, and the label attributes it to the weight reduction rather than the molecule. In the pooled pivotal studies it was reported by 7.1 percent of women and 0.5 percent of men on Zepbound, against 1.3 percent and 0 on placebo; nobody on drug stopped because of it.1 Telogen effluvium after rapid weight loss is well described, self-limiting, and not specific to any drug.

Special Populations

Adolescents

Not approved. Tirzepatide's paediatric obesity trials are ongoing and had not reported in a peer-reviewed journal as of this page's verification date; semaglutide has an adolescent indication and tirzepatide does not. Off-label use in adolescents is unstudied.

Pregnancy

The label states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, advises discontinuing when a pregnancy is recognised, and records that available human data are insufficient to evaluate drug-related risk; a pregnancy exposure registry exists. It also warns that tirzepatide may reduce the effectiveness of oral contraceptives, particularly at initiation and after each dose increase, and recommends a non-oral method or a barrier for four weeks after starting and after each escalation.1 That contraception warning is specific to tirzepatide and is routinely missed.

Regulatory Status

Where Is It Approved?

In the United States as Mounjaro for type 2 diabetes since May 2022, and as Zepbound for chronic weight management since November 2023 and for obstructive sleep apnoea since December 2024. In the European Union and the United Kingdom as Mounjaro, for both diabetes and weight management.1 The label was revised in January 2026 to add a multi-dose KwikPen and in August 2026 for the retinopathy warning; the current version is dated August 2026.

What Happened to Compounded Tirzepatide?

It became unlawful to make at scale. During the 2022 to 2024 shortage, compounders could produce copies under the FDA's shortage rules, and a large telehealth industry grew on it. On 19 December 2024 the FDA issued a declaratory order that the shortage was resolved. Enforcement discretion for state-licensed pharmacies ended on 18 February 2025 and for outsourcing facilities on 19 March 2025; courts denied injunctions against both deadlines. The FDA's position since is that "when a drug shortage is resolved, FDA generally considers the drug to be commercially available," and compounders may not regularly produce essentially identical copies.8

What followed was enforcement on two fronts. Lilly sued compounding pharmacies and telehealth companies through 2025 over products it said it "cannot validate the safety or effectiveness of."18 The FDA began issuing warning letters to telehealth firms in September 2025 and announced a second wave of 30 on 3 March 2026, citing claims of sameness with approved products and obscured sourcing.19 The sourcing page covers what remains of that market and what replaced it.

Related ONPEPS Coverage

What Would Change This Page

SURMOUNT-MMO, the placebo-controlled cardiovascular outcomes trial in obesity without diabetes, which would settle whether the extra weight loss buys extra protection. The Phase 3 MASH programme, which would create a liver indication. The adolescent trials. And the 2028 decision on whether the Medicare Bridge becomes permanent, which is an access question the cost page tracks.

References

Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: prescribing information. Revised August 2026. DailyMed. dailymed.nlm.nih.gov
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. Open access. pubmed.ncbi.nlm.nih.gov/35658024
Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26-36. Paywalled. pubmed.ncbi.nlm.nih.gov/40353578
Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. Paywalled. pubmed.ncbi.nlm.nih.gov/38078870
Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958-971. Paywalled. pubmed.ncbi.nlm.nih.gov/39536238
Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393(24):2409-2420. Paywalled. pubmed.ncbi.nlm.nih.gov/41406444
Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427-437. Paywalled. pubmed.ncbi.nlm.nih.gov/39555826
US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug Alerts and Statements. Content current as of 1 April 2026. fda.gov
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. Open access. pubmed.ncbi.nlm.nih.gov/34170647
Angelopoulos N, Zianni D, Livadas S, Androulakis I, Fousteris E, Paparodis R, et al. Six-month real-world effectiveness, persistence and safety of low-to-moderate dose tirzepatide in adults with obesity: a multicentre observational study. Diabetes Obes Metab. 2026. Open access. pubmed.ncbi.nlm.nih.gov/42037110
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. Paywalled. pubmed.ncbi.nlm.nih.gov/37385275
Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918. Open access. pubmed.ncbi.nlm.nih.gov/37840095
Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials. Ann Intern Med. 2025;178(2):199-217. Paywalled. pubmed.ncbi.nlm.nih.gov/39761578
Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205. Paywalled. pubmed.ncbi.nlm.nih.gov/38912654
Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299-310. Paywalled. pubmed.ncbi.nlm.nih.gov/38856224
Nissen SE, Wolski K, D'Alessio D, Weerakkody G, Kiljanski J, Wiese RJ, et al. Cardiorenal outcomes with tirzepatide compared with dulaglutide in patients with diabetes and cardiovascular disease: a post hoc analysis of the SURPASS-CVOT randomized clinical trial. JAMA Cardiol. 2026;11(6):544-552. Paywalled. pubmed.ncbi.nlm.nih.gov/41903177
Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. Open access. pubmed.ncbi.nlm.nih.gov/39996356
Eli Lilly and Company. Lilly statement on Mounjaro (tirzepatide) compounding litigation. Investor news release. investor.lilly.com
US Food and Drug Administration. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. Press announcement, 3 March 2026. fda.gov

Not Medical Advice

Tirzepatide is a prescription medicine with a boxed warning, contraindications and dose-escalation requirements set out in its label. Nothing here substitutes for that label or for a prescriber who has read it. Consult a qualified healthcare provider before acting on anything here.

Evidence counts on the library index retrieved 23 July 2026. Literature, label and regulatory sources verified 16 September 2026. The label, the compounding enforcement position and the Medicare programme all change frequently; re-verify before relying on any statement here.

Tirzepatide